<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367743</url>
  </required_header>
  <id_info>
    <org_study_id>2009-017081-23</org_study_id>
    <nct_id>NCT01367743</nct_id>
  </id_info>
  <brief_title>Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock</brief_title>
  <acronym>OptimaCC</acronym>
  <official_title>Optimizing the Use of Vasopressor After Coronary Reperfusion in Cardiogenic Shock Secondary to Myocardial Infarction. Pathophysiological Study Comparing the Efficacy and Cardio-circulatory Tolerability of Epinephrine and Norepinephrine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and tolerability of norepinephrine and epinephrine in cardiogenic shock after&#xD;
      reperfused myocardial infarction will be compared, by following cardiac index evolution as&#xD;
      main criteria. The study is a pilot pathophysiological study, randomized, double blind and&#xD;
      multicenter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiogenic shock secondary to myocardial infarction is a frequent pathology in reanimation&#xD;
      and is associated with high mortality (50%). Hemodynamic management and notably the choice of&#xD;
      vasopressor in cardiogenic shock states secondary to myocardial infarction (cardiac index &lt;&#xD;
      2.2 l/min/m-2) is not codified. There are two opposite views: a) the first is based on the&#xD;
      fact that an hypotensive patient with low cardiac output is primarily in need of an inotropic&#xD;
      agent and that, consequently, epinephrine is the molecule of choice (inotropic and&#xD;
      vasoconstrictor); b) the second is based on the fact that hypotension also reflects a certain&#xD;
      degree of vascular failure and vascular vasoplegia and therefore norepinephrine is the&#xD;
      molecule of choice along with, if needed, the eventual addition of dobutamine in order to&#xD;
      separately titrate vasoconstriction and inotropism.&#xD;
&#xD;
      Study hypotheses: epinephrine could facilitate myocardial function by providing the latter&#xD;
      with its preferred substrate (lactate) and thus induce a higher cardiac index along with&#xD;
      increased energy expenditure. Norepinephrine is the therapy of choice of hypotensive states;&#xD;
      nevertheless its lack of inotropic effect could theoretically exacerbate myocardial failure.&#xD;
      Thus, the aim of the study is to compared the efficiency and the tolerability of&#xD;
      norepinephrine and epinephrine in cardiogenic shock after reperfused myocardial infarction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compared effects of investigated drugs on cardiac index</measure>
    <time_frame>H0; H2, H4, H6, H12, H24, H48 and H72</time_frame>
    <description>effectiveness of the treatment assessed by the evolution of cardiac index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pro/anti-inflammatory cytokines</measure>
    <time_frame>H0, H24, H48 and H72</time_frame>
    <description>Compared effects of investigated drugs on pro/anti-inflammatory cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP</measure>
    <time_frame>H0, H24, H48 and H72</time_frame>
    <description>Compared effects of investigated drugs on BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin</measure>
    <time_frame>H0, H24, H48 and H72</time_frame>
    <description>Compared effects of investigated drugs on Troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>catecholamine doses</measure>
    <time_frame>H0, H24, H48 and H72</time_frame>
    <description>Compared effects of investigated drugs on the catecholamine doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>organ failure (SOFA Score)</measure>
    <time_frame>H0, H24, H48 and H72</time_frame>
    <description>Compared effects of investigated drugs on the organ failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate clearance</measure>
    <time_frame>H0, H2, H6, H12, H24 and H48</time_frame>
    <description>Compared effects of investigated drugs on the Lactate clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>H0, H2, H4, H6, H12, H24, H48 and H72</time_frame>
    <description>Compared effects of investigated drugs on heart rate and the incidence of arrhythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac power index</measure>
    <time_frame>H0, H2, H4, H6, H12, H24, H48 and H72.</time_frame>
    <description>Compared effects of investigated drugs on cardiac power</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVO2</measure>
    <time_frame>H0, H2, H4, H6, H12, H24, H48 and H72.</time_frame>
    <description>Compared effects of investigated drugs on the SVO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac double product</measure>
    <time_frame>H0, H2, H4, H6, H12, H24, H48 and H72.</time_frame>
    <description>Compared effects of investigated drugs on the cardiac double product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>refractory cardiogenic shock</measure>
    <time_frame>H0, H2, H4, H6, H12, H24, H48 and H72.</time_frame>
    <description>compared effects of the investigated drugs on the occurrence of refractory cardiogenic shock</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epinephrine perfusion</intervention_name>
    <description>perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg</description>
    <arm_group_label>epinephrine</arm_group_label>
    <other_name>vasopressor</other_name>
    <other_name>catecholamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norepinephrine perfusion</intervention_name>
    <description>perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg</description>
    <arm_group_label>norepinephrine</arm_group_label>
    <other_name>vasopressor</other_name>
    <other_name>catecholamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  man or woman older than 18 years&#xD;
&#xD;
          -  cardiogenic shock due to myocardial infarction treated by angioplasty&#xD;
&#xD;
          -  SAP &lt; 90 MM Hg or MAP &lt; 65 mm Hg without vasopressor or vasopressor necessity&#xD;
&#xD;
          -  sign of tissue hypoperfusion&#xD;
&#xD;
          -  cardiac index &lt; 2.2 l/mn/m2 in the absence of vasopressive or inotropic therapy&#xD;
&#xD;
          -  pulmonary artery occlusion pressure &gt; 15 mmHg or echocardiographic evidence of high&#xD;
             pressure (mitral profile)&#xD;
&#xD;
          -  exclusion of covert hypovolemia : Delta PP if feasible should be &gt; 13% (patient&#xD;
             adapted to the ventilator and sinus rhythm) and /or no response to passive leg raising&#xD;
&#xD;
          -  ejection fraction &lt; 40% in ultrasound without inotrope support. This criteria will not&#xD;
             be taken into account in instances of treatment with dopamine, norepinephrine,&#xD;
             epinephrine, dobutamine or milrinone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  shock of other origin&#xD;
&#xD;
          -  immediate indications for mechanical assistance device&#xD;
&#xD;
          -  minor aged patients&#xD;
&#xD;
          -  patients for whom written consent - by patient or family - has not been obtained.&#xD;
             Given the seriousness of the medical situation at the time of inclusion, patient&#xD;
             consent will be difficult if not impossible to obtain. The inclusion will only be&#xD;
             possible after information is provided and consent is obtained from a family member.&#xD;
             As soon as possible, protocol information will be issued to the patient in order to&#xD;
             obtain consent for continuance.&#xD;
&#xD;
          -  cardiac arrest with early signs of cerebral anoxia.&#xD;
&#xD;
          -  septic, toxic and obstructive cardiomyopathy&#xD;
&#xD;
          -  arrhythmogenic cardiomyopathy&#xD;
&#xD;
          -  patient with coronary insufficiency&#xD;
&#xD;
          -  patient with ventricular rhythm disorders&#xD;
&#xD;
          -  patient treated with a medicine listed in contre indication&#xD;
&#xD;
          -  patient without social assurance&#xD;
&#xD;
          -  patient major under legal protection or safeguard justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe VIGNON, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nancy Brabois university hospital</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Meurthe Et Moselle</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de BESANCON / Hôpital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de LIMOGES Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital NORD</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr Metz Thionville</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de MULHOUSE</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP-Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de STRASBOURG / NHC</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 10, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>epinephrine</keyword>
  <keyword>norepinephrine</keyword>
  <keyword>cardiac output</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>http://cic-p-nancy.fr/wp-content/uploads/2019/01/revUS_SAP_OPTIMA_CC_KD_NG.pdf</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

